KYOWA HAK KIRIN - Dusseldorf Stock Exchang (KY4 DU) stock market data APIs
€13.6867
0(0%)
as of December 17, 2025
Try our APIs with
free plan!
KYOWA HAK KIRIN - Dusseldorf Stock Exchang Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for KY4.DU.
Prev. Close
13.6867
Open
13.6867
High
13.6867
Low
13.6867
52 wk Range
12.1-15.3
Market Cap
13 438 M
EPS
34.44
Dividends (Yield)
2.0792
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get KYOWA HAK KIRIN - Dusseldorf Stock Exchang data using free add-ons & libraries
Get KYOWA HAK KIRIN - Dusseldorf Stock Exchang Fundamental Data
KYOWA HAK KIRIN - Dusseldorf Stock Exchang Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get KYOWA HAK KIRIN - Dusseldorf Stock Exchang Earnings data
$
19.99
/mo.
What’s included:
- Latest Release: 2024-10-31
- EPS/Forecast: 35.74
Get KYOWA HAK KIRIN - Dusseldorf Stock Exchang End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
KYOWA HAK KIRIN - Dusseldorf Stock Exchang News
New
Kura Oncology (KURA) Gains Momentum as Barclays Sees Significant Potential in Ziftomenib Approval
Kura Oncology Inc. (NASDAQ:KURA) is one of the stocks that will double in 2026. On November 24, Barclays analyst Etzer Darout raised the firm’s price target on Kura Oncology to $28 from $11 and main...
Kyowa Kirin (TSE:4151) Valuation Check as Shares Climb 11% Year to Date
Kyowa Kirin (TSE:4151) has been quietly grinding higher, with the stock up around 11% this year and roughly 7% over the past 3 months, hinting at improving sentiment around its drug pipeline. See our...
Kyowa Kirin Announces Proposed Appointment of Abdul Mullick to President and Chief Executive Officer, While Former CEO Masashi Miyamoto to Remain Chairman
Leadership Changes to Take Effect Following Conclusion of Ordinary General Meeting of Shareholders in March 2026 Announcement Follows Year of Dual CEO / COO Model and Returns Company to Single Leader ...
Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML
Kura Oncology, Inc. – 86% (32/37) CRc and 73% (27/37) CR in newly diagnosed NPM1-m AML, with 68% (17/25) of CRc responders achieving molecular MRD negativity by central NGS – Median duration of ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
